InMode (NASDAQ:INMD) Hits New 12-Month Low - Here's Why

InMode logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • InMode fell to a new 52-week low, trading as low as $12.61, below its prior close of $12.88.
  • Baird cut its price target from $17 to $15 and kept a Neutral rating; analysts’ average rating is Hold, with an average target of $16.33.
  • Quarterly EPS and revenue slightly beat estimates, but revenue declined 1.1% year over year and EPS slipped from $0.38 to $0.37.
  • Five stocks we like better than InMode.

InMode Ltd. (NASDAQ:INMD - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $12.61 and last traded at $12.6950, with a volume of 61,684 shares changing hands. The stock had previously closed at $12.88.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on INMD shares. Robert W. Baird lowered their price objective on shares of InMode from $17.00 to $15.00 and set a "neutral" rating for the company in a research note on Thursday, November 12th. Weiss Ratings raised InMode from a "sell (d)" rating to a "sell (d+)" rating in a research report on Tuesday. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, InMode has an average rating of "Hold" and an average target price of $16.33.

Read Our Latest Analysis on InMode

InMode Stock Performance

The firm has a fifty day moving average of $13.99 and a 200-day moving average of $14.25. The stock has a market capitalization of $732.37 million, a price-to-earnings ratio of 10.56 and a beta of 1.98.

InMode (NASDAQ:INMD - Get Free Report) last announced its earnings results on Wednesday, November 11th. The healthcare company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.05. InMode had a return on equity of 11.55% and a net margin of 19.94%. The company had revenue of $92.14 million during the quarter, compared to the consensus estimate of $91.58 million. During the same period last year, the firm earned $0.38 earnings per share. The company's revenue was down 1.1% on a year-over-year basis.

Institutional Trading of InMode

Several institutional investors have recently added to or reduced their stakes in INMD. IFP Advisors Inc bought a new position in shares of InMode in the 2nd quarter worth about $31,000. Parallel Advisors LLC grew its position in shares of InMode by 43.3% during the 3rd quarter. Parallel Advisors LLC now owns 4,934 shares of the healthcare company's stock valued at $70,000 after buying an additional 1,490 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in shares of InMode during the 3rd quarter valued at about $82,000. Hsbc Holdings PLC acquired a new stake in InMode during the first quarter worth about $163,000. Finally, Signaturefd LLC raised its stake in InMode by 50.0% during the third quarter. Signaturefd LLC now owns 12,014 shares of the healthcare company's stock worth $170,000 after acquiring an additional 4,006 shares during the period. Institutional investors own 68.04% of the company's stock.

InMode Company Profile

(Get Free Report)

InMode Ltd. is an Israel-based medical technology company that develops energy-based systems for minimally invasive aesthetic and medical procedures. Its technologies use radiofrequency energy to support treatments such as body contouring, skin tightening and facial rejuvenation, as well as certain women's health applications. The company's product portfolio includes platforms and handpieces such as BodyTite and FaceTite for body and facial contouring, and Morpheus8 for fractional radiofrequency skin treatments.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in InMode Right Now?

Before you consider InMode, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.

While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines